Triple negative breast cancer (TNBC) easily develops resistance to the first-line drug doxorubicin, because of the high levels of the drug efflux transporter P-glycoprotein (Pgp) and the activation of pro-survival pathways dependent on endoplasmic reticulum (ER). Interfering with these mechanisms may overcome the resistance to doxorubicin, a still unmet need in TNBC.
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
Salaroglio, Iris C;Gazzano, Elena;Mungo, Eleonora;Castella, Barbara;ABDELRAHMAN, GAMALELDEIN FATHY ABDELLATEF;Massaia, Massimo;Donadelli, Massimo;Riganti, Chiara
Co-last
;Kopecka, Joanna
Co-last
2018-01-01
Abstract
Triple negative breast cancer (TNBC) easily develops resistance to the first-line drug doxorubicin, because of the high levels of the drug efflux transporter P-glycoprotein (Pgp) and the activation of pro-survival pathways dependent on endoplasmic reticulum (ER). Interfering with these mechanisms may overcome the resistance to doxorubicin, a still unmet need in TNBC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Salaroglio, MS and Supporting, JECCR, 2018.pdf
Accesso aperto
Descrizione: Salaroglio, JECCR MS and Supporting, 2018
Tipo di file:
PDF EDITORIALE
Dimensione
10.13 MB
Formato
Adobe PDF
|
10.13 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
